QuidelOrtho Corporation announced the signing of a definitive agreement to form a joint venture between Ortho Clinical Diagnostics Trading, a subsidiary of QuidelOrtho, and Shanghai Medconn Biotechnology, a subsidiary of Shanghai Runda Medical Technology, to develop and manufacture assays in China for QuidelOrtho’s VITROS platform. QuidelOrtho develops IVD reagent products that meet the needs of the Chinese market with a significant installed base of VITROS immunodiagnostic analyzers, including but not limited to VITROS 3600 and 5600 instruments and the VITROS Automation System that connects these instruments, and has a leading position in quick turnaround STAT labs across China. Runda Medical is a leading IVD distributor in China and has developed its own family of instruments and assays. The JV will leverage both parties’ know-how in a range of incremental assays to broaden the VITROS test menu and gain efficiencies from local manufacturing at Runda Medical’s Shanghai facility. Both companies will contribute personnel and expertise to the joint venture and will share in the profits of the jointly developed products. Following an assay pilot program, both companies expect to begin developing a broader set of assays in early 2023 in parallel with building out the JV organization in the Shanghai and Beijing areas.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on QDEL: